Open AccessChanges in Apolipoprotein B100-Containing Lipoprotein Metabolism Due to an Estrogen Plus Progestin Oral Contraceptive: A Stable Isotope Kinetic Study
Author(s) -
Laurence Duvillard,
Guillaume Dautin,
E Florentin,
JeanMichel Petit,
Philippe Gambert,
Bruno Vergès
Publication year - 2010
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-2480
Subject(s) - apolipoprotein b , gestodene , endocrinology , medicine , very low density lipoprotein , chemistry , catabolism , lipoprotein , ethinylestradiol , metabolism , progestin , ldl receptor , estrogen , cholesterol , population , environmental health , family planning , research methodology
Oral contraceptives with estrogen plus progestin are likely to influence apolipoprotein B (apoB)-containing lipoprotein metabolism by changing the expression of different enzymes or receptors that play a major role in this metabolism. However, the precise changes in apoB kinetic parameters induced by oral contraceptives that are now currently used are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom